NAUT

MKT CAP:$333M

Nautilus Biotechnology, Inc.

Market Cap

$333M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$2.58+$0.67 (+35.08%)

Apr 23, 2026

Company Details

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that inclu...

CEO

Sujal Patel

IPO Date

Aug 7, 2020

Website

www.nautilus.bio

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$59M

EPS (Diluted)

-$0.47

Free Cash Flow

-$52M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

Apr 28, 2026

PENDING

FY 2025

Feb 26, 2026

$0EPS -$0.47

Q4 2025

Feb 26, 2026

$0EPS -$0.11

Q3 2025

Oct 28, 2025

$0EPS -$0.11

Q2 2025

Jul 31, 2025

$0EPS -$0.12

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	-$806.0K	-$16M
Q2 22	$0	-$829.0K	-$15M
Q3 22	$0	$0	-$16M
Q4 22	$0	-$921.0K	-$16M
Q1 23	$0	-$1M	-$18M
Q2 23	$0	-$1M	-$19M
Q3 23	$0	-$2M	-$19M
Q4 23	$0	-$2M	-$20M
Q1 24	$0	-$2M	-$22M
Q2 24	$0	-$2M	-$21M
Q3 24	$0	-$2M	-$19M
Q4 24	$0	-$6M	-$20M
Q1 25	$0	-$2M	-$19M
Q2 25	$0	-$2M	-$17M
Q3 25	$0	-$2M	-$15M
Q4 25	$0	-$2M	-$15M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$12M	-$13M
Q2 22	-$14M	-$14M
Q3 22	-$10M	-$11M
Q4 22	-$10M	-$11M
Q1 23	-$13M	-$13M
Q2 23	-$14M	-$14M
Q3 23	-$12M	-$13M
Q4 23	-$14M	-$14M
Q1 24	-$16M	-$17M
Q2 24	-$15M	-$16M
Q3 24	-$13M	-$14M
Q4 24	-$14M	-$15M
Q1 25	-$14M	-$14M
Q2 25	-$13M	-$14M
Q3 25	-$11M	-$11M
Q4 25	-$12M	-$13M

Capital Expenditures

Quarter	CapEx
Q1 22	$481.0K
Q2 22	$651.0K
Q3 22	$963.0K
Q4 22	$229.0K
Q1 23	$692.0K
Q2 23	$463.0K
Q3 23	$874.0K
Q4 23	$413.0K
Q1 24	$647.0K
Q2 24	$512.0K
Q3 24	$709.0K
Q4 24	$254.0K
Q1 25	$219.0K
Q2 25	$396.0K
Q3 25	$418.0K
Q4 25	$244.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+201.2%
Q2 22	—	+44.6%
Q3 22	—	+8.6%
Q4 22	—	-3.0%
Q1 23	—	+12.7%
Q2 23	—	+22.9%
Q3 23	—	+20.6%
Q4 23	—	+22.7%
Q1 24	—	+19.6%
Q2 24	—	+9.3%
Q3 24	—	+0.1%
Q4 24	—	-0.1%
Q1 25	—	-12.8%
Q2 25	—	-17.8%
Q3 25	—	-19.0%
Q4 25	—	-22.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$2M	—
Q2 22	$3M	—
Q3 22	$3M	—
Q4 22	$3M	—
Q1 23	$3M	—
Q2 23	$0	—
Q3 23	$3M	—
Q4 23	$3M	—
Q1 24	$3M	—
Q2 24	$3M	—
Q3 24	$3M	—
Q4 24	$3M	—
Q1 25	$2M	—
Q2 25	$2M	—
Q3 25	$1M	—
Q4 25	$1M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$9M	—	$6M
Q2 22	$9M	—	$6M
Q3 22	$10M	$6M	—
Q4 22	$9M	—	$6M
Q1 23	$10M	—	$6M
Q2 23	$12M	—	$6M
Q3 23	$11M	—	$6M
Q4 23	$12M	—	$7M
Q1 24	$12M	—	$8M
Q2 24	$12M	—	$7M
Q3 24	$12M	—	$6M
Q4 24	$11M	—	$3M
Q1 25	$11M	—	$6M
Q2 25	$10M	—	$6M
Q3 25	$9M	—	$5M
Q4 25	$11M	$6M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$189M	$135M	$324M
Q2 22	$210M	$89M	$299M
Q3 22	$189M	$69M	$258M
Q4 22	$115M	$70M	$184M
Q1 23	$89M	$79M	$167M
Q2 23	$72M	$91M	$163M
Q3 23	$74M	$109M	$183M
Q4 23	$19M	$154M	$173M
Q1 24	$26M	$156M	$181M
Q2 24	$25M	$143M	$167M
Q3 24	$4M	$136M	$141M
Q4 24	$28M	$102M	$130M
Q1 25	$33M	$106M	$139M
Q2 25	$34M	$113M	$148M
Q3 25	$24M	$108M	$131M
Q4 25	$12M	$91M	$103M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	124M	+0.1%	+292.1%
Q2 22	124M	+0.1%	+126.1%
Q3 22	125M	+0.1%	+0.4%
Q4 22	125M	+0.1%	+0.4%
Q1 23	125M	-0.2%	+0.1%
Q2 23	125M	+0.0%	+0.1%
Q3 23	125M	+0.3%	+0.2%
Q4 23	125M	+0.0%	+0.2%
Q1 24	125M	+0.1%	+0.4%
Q2 24	125M	+0.1%	+0.6%
Q3 24	125M	+0.1%	+0.4%
Q4 24	126M	+0.3%	+0.6%
Q1 25	125M	-0.7%	-0.2%
Q2 25	126M	+1.0%	+0.7%
Q3 25	126M	+0.0%	+0.6%
Q4 25	126M	+0.0%	+0.4%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	113
Q2 22	$0	113
Q3 22	$0	113
Q4 22	$0	134
Q1 23	$0	134
Q2 23	$0	134
Q3 23	$0	134
Q4 23	$0	167
Q1 24	$0	167
Q2 24	$0	167
Q3 24	$0	167
Q4 24	$0	155
Q1 25	$0	155
Q2 25	$0	155
Q3 25	$0	155
Q4 25	$0	130

Revenue / Employee